Sampharm Labs Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 16-11-2024
- Paid Up Capital ₹ 0.30 M
as on 16-11-2024
- Company Age 4 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.96 M
as on 16-11-2024
- Revenue -27.77%
(FY 2023)
- Profit -94.07%
(FY 2023)
- Ebitda 111.88%
(FY 2023)
- Net Worth 403.40%
(FY 2023)
- Total Assets 82.30%
(FY 2023)
About Sampharm Labs
The Company is engaged in the Fmcg Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.30 M.
The company currently has active open charges totaling ₹5.96 M.
Thanzil Ishrathulla and Imran Farooqi serve as directors at the Company.
- CIN/LLPIN
U24231KA2020PTC138613
- Company No.
138613
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Sep 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Sampharm Labs?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Thanzil Ishrathulla  | Director | 15-Sep-2020 | Current |
| Imran Farooqi | Director | 15-Sep-2020 | Current |
Financial Performance of Sampharm Labs.
Sampharm Labs Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 27.77% decrease. The company also saw a substantial fall in profitability, with a 94.07% decrease in profit. The company's net worth Soared by an impressive increase of 403.4%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sampharm Labs?
Unlock access to Sampharm Labs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Sam Gypsum Private LimitedActive 11 years 4 daysThanzil Ishrathulla and Imran Farooqi are mutual person
Sam Farmpro Industries Private LimitedActive 4 years 4 monthsThanzil Ishrathulla and Imran Farooqi are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Uco Bank Creation Date: 28 Sep 2022 | ₹5.00 M | Open |
Uco Bank Creation Date: 19 Nov 2020 | ₹0.96 M | Open |
How Many Employees Work at Sampharm Labs?
Sampharm Labs has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sampharm Labs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sampharm Labs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
